ijms-logo

Journal Browser

Journal Browser

Advanced Functionalization of Biopolymers and Bio-Oligomers for Precision Therapeutics

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Materials Science".

Deadline for manuscript submissions: 28 February 2026 | Viewed by 703

Special Issue Editor


E-Mail Website
Guest Editor
Laboratory of Biopharmaceuticals and Molecular Pharmacology, School of Pharmaceutical Sciences, Hainan University, Haikou, Hainan 570228, China
Interests: biopharmaceuticals; biopolymers; targeted drug design; molecular dynamics; molecular biology; pharmaceutical experiments
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue aims to focus on the advanced functionalization of biopolymers and bio-oligomers, a pivotal basis for precision therapeutic intervention. In pharmaceutics, this topic covers supportive drug delivery designs that complement biotherapeutic action. Its core lies in biopharmaceuticals: through tailored functionalization, these agents (e.g., targeted antibody–drug conjugates and peptide/nucleic acid therapeutics) are engineered to precisely target disease-specific loci—such as cancer cell-specific antigens, pathogenic protein isoforms in metabolic disorders, or infected cells in infectious diseases—directly engaging with root pathogenic targets. Pharmacologically, this precision ensures that biopharmaceuticals act only on diseased sites, avoiding non-targeted tissue impact while boosting curative effects. Collectively, this Special Issue aims to integrate cutting-edge progress to advance biopharmaceuticals’ role in precise disease treatment, accelerating their clinical translation.

Prof. Dr. Dayong Wang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • precision therapeutics
  • biopolymers
  • drug delivery
  • biopharmaceuticals
  • pharmacology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 5982 KB  
Article
Structure-Guided Design of Cyclic Peptide: A Potent Inhibitor Targeting PD-1/PD-L1 Axis with Antitumor Activity
by Wenyu Peng, Wenyu Gu, Wujuan Chen, Jiazheng Zhao, Nuela-Manka’a Che Ajuyo, Yechun Pei, Yi Min and Dayong Wang
Int. J. Mol. Sci. 2025, 26(23), 11308; https://doi.org/10.3390/ijms262311308 - 22 Nov 2025
Viewed by 524
Abstract
Blocking the protein–protein interaction (PPI) between programmed cell death protein 1 (PD-1) and its ligand PD-L1 is a crucial strategy in cancer immunotherapy. However, existing monoclonal antibody-based therapies have limitations such as high production costs and poor tumor penetration. In this study, we [...] Read more.
Blocking the protein–protein interaction (PPI) between programmed cell death protein 1 (PD-1) and its ligand PD-L1 is a crucial strategy in cancer immunotherapy. However, existing monoclonal antibody-based therapies have limitations such as high production costs and poor tumor penetration. In this study, we developed a novel cyclic peptide inhibitor, PD-1-0520, through structure-based design. Starting from key fragments of PD-L1 that interact with PD-1, we designed 5 mimetic peptides and further optimized them into 22 cyclic peptide candidates. Through molecular dynamics screening and in vitro and in vivo experimental validation, PD-1-0520 was proven to have potent antitumor activities. Results showed that PD-1-0520 effectively inhibited the PD-1/PD-L1 interaction, restored the immune activity of tumor-infiltrating T cells, and achieved a 68% tumor inhibition rate in B16-F10 tumor-bearing mice without systemic toxicity. It promoted CD8+ T cell infiltration into tumors and upregulated activation markers, remodeling the tumor immune microenvironment. These findings demonstrate that PD-1-0520 is a promising immune checkpoint inhibitor, and our design strategy provides a new approach for developing PPI-targeting bioactive inhibitors. Full article
Show Figures

Figure 1

Back to TopTop